Amgen's growth medicines are running into three different access barriers.

Sales are moving in both directions, and each medicine faces a different access barrier.

Sales change, Q2 2026 vs Q2 2025, on one shared scale. Barriers from a sample of 4 payer policies and 1 Amgen posting, checked Nov 2, 2026. Amgen doesn't disclose EVENITY sales separately.

Source: Amgen Q2 2026 earnings call highlights (via GuruFocus, Aug 4, 2026); payer policies and Amgen posting as named, checked Nov 2, 2026. Ben Aylesworth analysis.

Three barriers, three moves, each aimed at a specific line in a payer's own policy.

It's the job I did running Aidoc's NTAP reimbursement rollout to more than 40 hospital customers: find the exact line in a payer's written policy that keeps an approved product from its patient, then build what moves that line.

1. TEZSPIRE

   Measuredays from prescription to PA approval

   Turn prior authorization into a pre-filled form

   Every PA form asks for the same few facts: prior controller therapies, exacerbation history, eosinophil counts.

   First move. Map the 5 to 10 highest-volume payer policies by the fields each one asks for, then build the submission tool on that shared field set.

2. EVENITY

   Measureoverride approvals at the sampled plans

   Build the step-therapy override case while exclusivity holds

   Prolia and XGEVA just showed what biosimilars do to a bone franchise. EVENITY is next in line.

   First move. A payer-by-payer evidence package tied to each plan's own bisphosphonate-intolerance criteria, ready before a provider hits the denial.

3. IMDELLTRA

   Measurevalue messages accepted, by market

   Track which payer value messages land as the indication expands

   Amgen's own posting describes value messages being tested with payers across the US, Europe, Canada, Japan and Asia-Pacific.

   First move. A shared record of which value messages each payer accepted or pushed back on, market by market, as the expansion evidence arrives.